PHASE 2 STUDY OF PEMBROLIZUMAB PLUS TTFIELDS PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)

被引：0
|
作者：
Tran, David [1 ]
Ghinaseddin, Ashley [2 ]
Chen, Dongjiang [2 ]
Rahman, Maryam [2 ]
机构：
[1] Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL USA
[2] Univ Florida, Gainesville, FL USA
来源：
NEURO-ONCOLOGY | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CTIM-16
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [41] PHASE I STUDY OF IBRUTINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Rauf, Yasmeen
    Peereboom, David
    Fallah, Jaleh
    Schilero, Cathy
    Lackner, Pamela
    Stevens, Glen
    Ahluwalia, Manmeet
    NEURO-ONCOLOGY, 2020, 22 : 37 - 37
  • [42] Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
    Butowski, N. A.
    Lamborn, K.
    Chang, S.
    Thornton, D.
    DeBoer, R.
    Page, M.
    Rabbitt, J.
    Parvanateni, R.
    Kivett, V.
    Nicol, S.
    Prados, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
    Reyes-Botero, German
    Cartalat-Carel, Stephanie
    Chinot, Olivier L.
    Barrie, Maryline
    Taillandier, Luc
    Beauchesne, Patrick
    Catry-Thomas, Isabelle
    Barriere, Jerome
    Guillamo, Jean-Sebastien
    Fabbro, Michel
    Frappaz, Didier
    Benouaich-Amiel, Alexandra
    Le Rhun, Emilie
    Campello, Chantal
    Tennevet, Isabelle
    Ghiringhelli, Francois
    Tanguy, Marie-Laure
    Mokhtari, Karima
    Honnorat, Jerome
    Delattre, Jean-Yves
    ONCOLOGIST, 2018, 23 (05): : 524 - +
  • [44] A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma
    Huang J.
    Campian J.L.
    DeWees T.A.
    Skrott Z.
    Mistrik M.
    Johanns T.M.
    Ansstas G.
    Butt O.
    Leuthardt E.
    Dunn G.P.
    Zipfel G.J.
    Osbun J.W.
    Abraham C.
    Badiyan S.
    Schwetye K.
    Cairncross J.G.
    Rubin J.B.
    Kim A.H.
    Chheda M.G.
    International Journal of Radiation Oncology Biology Physics, 120 (03): : 738 - 749
  • [45] Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Younes, Anas
    Oki, Yasuhiro
    McLaughlin, Peter
    Copeland, Amanda R.
    Goy, Andre
    Pro, Barbara
    Feng, Lei
    Yuan, Ying
    Chuang, Hubert H.
    Macapinlac, Homer A.
    Hagemeister, Fredrick
    Romaguera, Jorge
    Samaniego, Felipe
    Fanale, Michelle A.
    Dabaja, Bouthaina Shbib
    Rodriguez, Maria A.
    Dang, Nam
    Kwak, Larry W.
    Neelapu, Sattva S.
    Fayad, Luis E.
    BLOOD, 2012, 119 (18) : 4123 - 4128
  • [46] Phase III TRIDENT trial: Radiation and temozolomide plus /- tumor treating fields in newly diagnosed glioblastoma.
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel Aaron
    Nagpal, Seema
    Reardon, David A.
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Lim, Michael
    Weller, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju R.
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie W.
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Sahebjam, Solmaz
    Mellinghoff, Ingo K.
    Kinoshita, Masashi
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Leung, David
    Lee, Michelle
    Reardon, David A.
    Omuro, Antonio
    NEURO-ONCOLOGY, 2022, 24 (11) : 1935 - 1949
  • [48] EF-32 (TRIDENT): A pivotal phase 3 randomized trial of concomitant radiation therapy and temozolomide plus /- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma
    Glas, M.
    Kleinberg, L.
    Jeyapalan, S.
    Goldlust, S.
    Nagpal, S.
    Combs, S.
    Roberge, D.
    Nishikawa, R.
    Reardon, D.
    Grossman, R.
    Shi, W.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S97 - S98
  • [49] A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501)
    Rosenfeld, M. R.
    Chamberlain, M. C.
    Grossman, S. A.
    Peereboom, D. M.
    Lesser, G. J.
    Batchelor, T. T.
    Desideri, S.
    Salazar, A. M.
    Ye, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] PHASE III TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) TOGETHER WITH TEMOZOLOMIDE (TMZ) COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Farber, Ori
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2013, 15 : 76 - 77
12345